This page lists the SEC filings reported by Cross Nicholas John.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2022-03-17 | Cross Nicholas John | Immunocore Holdings plc | 2,369,610 | 5.4% | EDGAR |
| SC 13G/A | 2019-02-14 | Cross Nicholas John | Adaptimmune Therapeutics PLC | 29,042,800 | 4.6% | EDGAR |
| SC 13G/A | 2018-02-02 | Cross Nicholas John | Adaptimmune Therapeutics PLC | 29,042,800 | 5.2% | EDGAR |
| SC 13G/A | 2017-02-03 | Cross Nicholas John | Adaptimmune Therapeutics PLC | 29,322,178 | 6.9% | EDGAR |
| SC 13G | 2016-03-25 | Cross Nicholas John | Adaptimmune Therapeutics PLC | 29,042,800 | 6.8% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.